PLOZALIZUMAB PLEVISTINAG
UNII P5H59ZL4XA

Substance Identification & Data

This profile provides standardized clinical and technical data for Plozalizumab Plevistinag, uniquely identified by the FDA Unique Ingredient Identifier (UNII) P5H59ZL4XA.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2983832-01-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
P5H59ZL4XA
CAS Registry Number
2983832-01-3
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
PLOZALIZUMAB PLEVISTINAG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C185129
National Cancer Institute reference terminology for clinical and research data.
INN ID
13431
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
protein
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Plozalizumab Plevistinag. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

Common Names & Synonyms

IMMUNOGLOBULIN G1, ANTI-(HUMAN CC CHEMOKINE RECEPTOR CCR2) (HUMAN-MUS MUSCULUS MONOCLONAL 1D9 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL 1D9 .KAPPA.-CHAIN, DIMER, THIOETHER WITH (P(R))-2'-DEOXY-2'-FLUORO-5'-O-((R)-HYDROXYMERCAPTOPHOSPHINYL)-N-(2-(((((4-((6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-N-(1-OXO-4,7,10,13,16,19,22,25-OCTAOXAHEXACOS-1-YL)-L-NOVLEUCYL-L-VALYL-L-ALANYL)AMINO)PHENYL)METHOXY)CARBONYL)METHYLAMINO)METHYL)BENZOYL)-P-THIOADENYLYL-(3'->5')-7-FLUORO-7-DEAZAINOSINE CYCLIC (2'->5')-NUCLEOTIDE
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CCR2 (CHEMOKINE (C-C MOTIF) RECEPTOR 2, C-C CHEMOKINE RECEPTOR 2, CC-CKR-2, CKR-2, MONOCYTE CHEMOATTRACTANT PROTEIN 1 RECEPTOR, MCP-1-R, CD192)), HUMANIZED MONOCLONAL ANTIBODY, CONJUGATED, ON AN AVERAGE OF 3.8-4.4 CYSTEINYL RESIDUES, TO DAZOSTINAG (A STING AGONIST) VIA A CLEAVABLE LINKER
PLOZALIZUMAB PLEVISTINAG
PLOZALIZUMAB PLEVISTINAG [INN]

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus